Official Journal of Research Center for Gastroenterology and Liver Diseases
Authors
Thyroid dysfunction (TD) represents an extra-hepatic manifestation of chronic hepatitis C (CHC) and it may also be a side effect of interferon-alpha (IFN-?) based treatment. However, previous studies have shown a wide variation in the incidence of TD in patients with CHC. Furthermore, the long-term outcomes and the predictive factors of TD in patients who receive IFN-? based treatment have still not been fully studied.
The purpose of this study was to describe the incidence and long-term outcomes of TD in Chinese patients with CHC receiving IFN-? based treatment. We also aimed to identify the predictive factors of TD associated with this type of therapy.
A retrospective case-series study of 592 consecutive CHC patients with normal baseline thyroid functions, who received IFN-?based therapy, was performed. Thyroid function was assessed at baseline and every three months during treatment, as well as in the follow-up after cessation of therapy. The incidence and long-term outcomes of TD were observed. The prevalence of pretreatment thyroid peroxidase antibodies (TPOAb) were assayed in a sex- and age-matched nested case-control study. Multivariable stepwise regression analysis was used to explore the independent effects of the baseline factors, on the incidence of TD.
At the end of the IFN-?based therapy, 68 patients (11.5%) in the study had developed TD, 58 patients (85.3%) presented with subclinical TD, and only 10 patients (14.7%) developed overt thyroiditis. The thyroid function of 46 patients (67.8%) spontaneously returned to normal in the six months of follow-up and only three patients (4.4%) had persistent overt TD symptoms after the 24 month follow-up period. Multivariate stepwise analysis suggested that gender and pretreatment TPOAb were the independent factors related to the incidence of TD. Both female patients (OR, 4.31; 95%CI, 2.067.31; P = 1.2610-4) and participants with a positive pretreatment TPOAb (OR = 3.9, 95%CI, 1.728.54, P = 0.008) had an increased risk for the development of TD.
The incidence of TD in Chinese patients with CHC during IFN-?based therapy was 11.5%, the majority of which was subclinical, while only a very small group had long-term overt TD requiring ongoing medical therapy. Female gender and pretreatment TPOAb positivity are risk factors for the development of TD during IFN-?based therapy.
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Ziaee A, Esfehanian F, Sarreshtedari M. Thyroid Dysfunction in Patients with Chronic Viral Hepatitis B and C during Alpha Interferon Therapy. Hepat Mon. 2009;9(2):. doi:
Nadeem A, Hussain M, Aslam M, Hussain T. Interferon-Alpha Induced and Ribavirin Induced Thyroid Dysfunction in Patients with Chronic Hepatitis C. Hepat Mon. 2010;10(2):. doi:
Rahimi MA, Sayad B, Tahamoli Roudsari A, Shahebrahimi K, Shirvani M, et al. Autoimmune thyroid disorder in patient with chronic hepatitis C before treatment. J Kermanshah Univ Med Sci. 2011;15(3):e79361. doi:
Wu Q, Zhan FY, Chen EQ, Wang C, Li ZZ, et al. Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China. Hepat Mon. 2015;15(6):e28836. doi: https://doi.org/10.5812/hepatmon.15(6)2015.28836
Tran H, Jones T, Ianna E, Gibson R, Reeves G. The Reduced Predictive Value of Interleukin 28b Gene Polymorphisms in a Cohort of Patients With Thyroiditis Developed During Antiviral Therapy for Chronic Hepatitis C: A Preliminary Study. Hepat Mon. 2012;12(8):6036. doi: https://doi.org/10.5812/hepatmon.6036
Last Update: 2 weeks ago
Last Update: 2 weeks ago
Last Update: 2 weeks ago
Last Update: 5 hours ago
Last Update: 10 hours ago
Last Update: 5 days ago
